Thomas Powles discusses the key findings from the biomarker analyses of the JAVELIN Bladder 100 study of maintenance avelumab in patients with advanced urothelial cancer (3:56).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany